News overview

News
27 July 2022
Oncode Investigator Madelon Maurice receives KWF funding for innovative SureTAC technology
At the start of the year, Argobio and Oncode have teamed up with Oncode Investigator Madelon Maurice (UMCU) and launched Laigo Bio, a new spin-off from the University Medical Center Utrecht (UMCU) in the emerging field of targeted protein degradation. Now, KWF has announced that this public-private collaboration will receive 1.2 million euros subsidy from the PPP allowance that Health~Holland makes available to KWF from the top sector Life Sciences & Health (LSH).


News
26 July 2022
New research puts the mode-of-action of T-cell immunotherapies in focus
A new 3D imaging and analysis technique, developed in Oncode Investigator Anne Rios’ lab at the Princess Máxima Center , brings the working mode of T-cell immunotherapies into live view. Researchers plan to use the new imaging technique to improve T-cell therapies for solid tumors. The results of this collaborative research endeavor were published today in the leading journal Nature Biotechnology.


News
14 July 2022
Looking towards the future, together
On July 4th and 5th, almost 400 Oncode researchers gathered in De Rijtuigenloods in Amersfoort, indulging themselves in hot-of-the-press science conducted by their colleagues. Participants had the opportunity to listen to more than 20 scientific talks, divided in six research subjects spanning all the Oncode research fields, gather around posters and discuss the latest findings – and, of course, enjoy each other’s company and do live networking over coffee and drinks.


News
13 July 2022
Exciting research from the Kops and van Rheenen labs now published in Nature
The research team of Oncode Investigator Geert Kops (Hubrecht Institute) reports that the 3D location of chromosomes in the interphase cell nucleus affects how likely they are to be incorrectly transmitted to daughter cells. The results of their study highlight yet another functional role of 3D genome organization in cells. Oncode Investigator Jacco van Rheenen (NKI) and his research team filmed stem cells in the colon and small intestine and found different levels of stem cell regulation, which has a major impact on the onset of cancer.


News
12 July 2022
Oncode-PACT foundation officially established
Oncode Institute is proud to announce that it has officially established the Oncode-PACT foundation. The set-up of this foundation is an important step to receive the National Growth Fund (NGF) subsidy and to get the Oncode-PACT initiative up and running.


News
6 July 2022
Oncode Investigators Marvin Tanenbaum and Michiel Vermeulen were honoured with the prestigious EMBO membership
Oncode Institute is proud to announce that two Oncode Investigators were honoured with the prestigious EMBO membership. The membership recognizes outstanding achievements in the life sciences and members are actively involved in the EMBO organization


News
30 June 2022
Vidi Grants awarded to Miao-Ping Chien, Rebekka Schneider, Tineke Lenstra and Monique Mulder
Oncode Institute is proud to announce that three Oncode Investigators and one Oncode Researcher will receive a Vidi Grant worth 800.000 euros. This grant will enable Oncode Investigators Miao-Ping Chien, Rebekka Schneider (both Erasmus MC), Tineke Lenstra (Netherlands Cancer Institute) and Oncode Researcher Monique Mulder (Leiden UMC) to develop their own innovative line of research and set up their own research group in the coming five years.


News
27 June 2022
Prostate cancer hijacks tumor cell biorhythm to evade hormone therapy
Hormone therapy is successful at keeping metastatic prostate cancer under control, but eventually the tumor cells become resistant to it. An unexpected potential solution has now emerged in medicines not designed to fight cancer, but to target proteins that regulate a cell’s circadian rhythm. Oncode Investigator Wilbert Zwart and others publish about this discovery in cancer discovery today.


News
21 June 2022
Cell-free DNA biomarkers can help to identify treatment responders and non-responders of head and neck cancer patients
The team of Jeroen de Ridder finalized a Clinical Proof of Concept (CPoC) study in which they tested the feasibility of circulating tumor DNA (ctDNA) analysis in head- and neck cancer patients as treatment response identifier. Their results are promising and more extensive validation in larger patient cohorts is underway.


News
10 May 2022
Cancer Research UK forms strategic alliance with Oncode Institute
Cancer Research UK, the world’s largest private funder of cancer research, today announces a strategic alliance with Oncode Institute. The five-year partnership is the first under Cancer Research UK’s new innovation organisation, Cancer Research Horizons, as well as being Oncode’s first UK partner. The alliance aims to foster innovation and collaboration between world-leading cancer researchers.

Scroll for more